The efficacy of intravitreal aflibercept given in a 'treat and extend' regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

Trial Profile

The efficacy of intravitreal aflibercept given in a 'treat and extend' regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal oedema
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 2 May 2016 to 2 Feb 2019.
    • 08 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top